Improving Care

Reducing morbidity and mortality and enhancing quality of life

Informing Policy

Transforming health care at the local, national and international levels

Featured Projects

With more than 80 scientists, research at Advancing Health encompasses a wide breadth of areas


The Evidence Speaks

A recurring feature highlighting the latest in Advancing Health research

Our People

In the News

Research Resources

From design to execution, Advancing Health provides a broad range of support services

Work in Progress Seminar Series

Larry D. Lynd

Scientist, PHD, BSP

Dr. Larry Lynd is a Professor and the Dean pro tem in the University of British Columbia (UBC) Faculty of Pharmaceutical Sciences and is the Director of the Collaboration for Outcomes Research and Evaluation.

Research Interests

  • Pharmacoeconomics
  • Pharmacoepidemiology
  • Health services research
  • Asthma
  • Risk-benefit analysis
  • Health economics
  • Outcomes research
  • Longitudinal analysis
  • Toxicology
  • Population health

Additionally, he is an Associate of the UBC School of Population and Public Health, and a Scholar at the Peter Wall Institute for Advanced Studies at UBC.

Formerly, he was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research (CIHR) New Investigator.

Dr. Lynd has more than 200 peer-reviewed publications, book chapters, and research abstracts. Recently, he was appointed as the Chair of the Health Canada Special Advisory Committee on Nonprescription Drugs, and to the Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, and he sits as the economics expert on the B.C. Ministry of Health Services Expensive Drugs for Rare Diseases Committee. His primary research interests are in the areas of risk-benefit analysis, pharmacoepidemiology, health economics, and policymaking for drugs for rare diseases. He is the principal investigator on the CIHR New Emerging Team for Rare Diseases, focused on policy and decision-making for orphan drugs. Projects include Million Dollar Meds.